Trial Profile
Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders: a Pilot Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Dermatomyositis; Juvenile rheumatoid arthritis; Polyarthritis; Psoriatic arthritis; Systemic lupus erythematosus; Systemic vasculitis
- Focus Therapeutic Use
- 04 Dec 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2021.
- 16 Aug 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2021.